A significant survival improvement finding for adults with newly diagnosed BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia appears in the New England Journal of Medicine. The practice-changing finding is from the randomized phase 3 study E1910, which evaluated blinatumomab immunotherapy in patients who were in remission and tested negative for measurable residual disease (MRD) after an initial round of chemotherapy.
Medical Xpress – latest medical and health news stories
Discover more from Nurse Unity Chats
Subscribe to get the latest posts sent to your email.